On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...